CClinicalTrials.gg
RecruitingNCT05123963TIMEDUpdated May 11, 2026

Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors

An interventional study of High-intensity interval training in Prediabetic State, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

Exercise is well-known to improve skeletal muscle energy metabolism and is an established intervention to improve muscle insulin sensitivity and to counter the development of type 2 diabetes (T2D). However, given the 24h rhythmicity in substrate metabolism previously observed in healthy, lean men and the lack of such rhythmicity in men with insulin-resistance, the investigator hypothesize that appropriate timing of exercise training can maximize the metabolic health effects of exercise. Indeed, a preliminary study in humans revealed that afternoon high-intensity interval training (HIIT) exercise was more effective than morning exercise in improving 24h blood glucose levels in men with T2D. Another recent study in mice showed that the time of day is a critical factor in augmenting the beneficial effects of exercise on the skeletal muscle metabolome as well as on whole-body energy homeostasis. However, human studies that specifically target the impact of timing of exercise training on glucose homeostasis and metabolic health are scarce and the potential underlying mechanisms largely unknown.

The overarching goals of this project is to improve 24-hour rhythmicity of metabolism in men and women with prediabtes by appropriate timing of exercise and to assess its effect on metabolic health and immune response. Acute and prolonged exercise interventions timed in the morning vs late afternoon will be carried out in individuals with prediabetes to determine whether acute exercise in the afternoon and prolonged exercise training in the afternoon can improve peripheral insulin sensitivity, compared to exercise in the morning, and positively affect adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles.

Read the detailed description

Three metabolic studies A, B and C using PET imaging will be carried out at the CRCHUS. The 12-week exercise training intervention will consist of supervised cycling high-intensity interval training (i.e. short bouts of high-intensity exercise interspersed with short periods of rest) every other day at the CRCHUS. Continuous glucose monitoring will be used to measure 24h glucose profiles over 3-4 days prior to and following the acute exercise bout and again during the last week of the intervention. Continuous blood pressure monitoring will be used over 18-24 h, at the beginning and at the end of the 12 week-training.

Participants will take part in three postprandial metabolic studies: 1) before (A); 2) 18-24h after an acute exercise bout (B), and; 3) after 12-weeks of exercise training (C). Experiments will be conducted between 07:30 AM and 5:00 PM, following a 12 hr fast. Adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles will be measured by the oral [18F-]-FTHA PET method. Changes in lean tissue mitochondrial function in vivo will be determined using magnetic resonance spectroscopy (MRS). Participants will complete Visit A (baseline), followed 7 to 14-days later by a pre-breakfast (9 AM) or pre-dinner (4PM) exhaustive glycogen lowering exercise bout. The following day (18-24h after the exercise bout), participants will return for a second metabolic visit (Visit B). Participants will then begin a 12-week supervised high-intensity interval training program, performed either only in the morning or only in the afternoon (9 AM vs. 4 PM), on every other day. At the end of the 12 weeks, and at least 48h after the last exercise bout, participants will return for their final metabolic visit (Visit C).

02

Conditions studied

  • Prediabetic State

Browse trials for

Keywords

  • Postprandial metabolism
  • High-intensity interval training
03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

This study's planned enrollment of 48 is below the median of 65 across 844 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Université de Sherbrooke is the lead sponsor of 289 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Pre-diabetes:

    • Fasting plasma glucose: 6.1 to 6.9 mmol/L or
    • 2-hour plasma glucose post 75g OGTT: 7.8 to 11.0 mmol/L and
    • HbA1c: 6.0 to 6.4%
    • or Insulin resistant: glucose clearance rate ≤ 360 ml/kg/min as determined using the Oral Glucose Insulin Sensitivity Index at Time 120 min.
  • BMI > 25 kg/m2
  • To be willing and able to adhere to the specifications of the protocol;
  • To have signed an informed consent document indicating that they understood the purpose of and procedures required for the study and were willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG
  • Treatment with any drug known to affect lipid or carbohydrate metabolism, except statins (to be stopped 3 weeks prior to study A), metformin or anti-hypertensive drugs (to be stopped 7 days prior to the studies);
  • presence of liver or renal disease other than uncomplicated NASH or mild isolated proteinuria; uncontrolled thyroid disorder;
  • Uncontrolled severe hypertension, systolic pressure ≥ 180 mm Hg or diastolic pressure ≥ 110 mm Hg;
  • History of ischemic heart disease, tachyarrhythmia, QT interval prolongation, risk factors for torsade de pointes (eg hypokalemia), or taking any medication known to prolong the QT interval;
  • History of serious gastrointestinal disorders (malabsorption, peptic ulcer, gastroesophageal reflux requiring surgery, etc.);
  • Presence of a pacemaker;
  • Having undergone a PET study or CT scan in the past year;
  • Any contraindication to stopping statins for 3 months and stopping an anti-hypertensive medication and metformin for 7 days;
  • smoking (>1 cigarette/day) and/or consumption of >2 alcoholic beverages per day;
  • No blood donation two month prior the study;
  • prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting TG > 6 mmol/l.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Morning exercise

    Participant to perform high-intensity interval training in the morning (\~9 am)

    Behavioral: High-intensity interval training

  • Experimental
    Afternoon exercise

    Participant to perform high-intensity interval training in the morning (\~4 pm)

    Behavioral: High-intensity interval training

Interventions

  • BehavioralHigh-intensity interval training

    3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Adipose tissue dietary fatty acid (DFA) partitioning

    Determined using oral administration of \[18F\]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition

    Time frame: Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  2. Change in lean organ (heart, liver, skeletal muscle) DFA partitioning

    Determined using oral administration of \[18F\]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition

    Time frame: Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  3. Change in skeletal muscle ATP fluxes in vivo

    Determined using phosphorus-31 magnetic resonance spectroscopy.

    Time frame: Measured 170 minutes before and 30 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  4. Change in glucose control.

    Determined using continuous glucose monitoring and repeated blood samples obtained during metabolic visit.

    Time frame: Measured continuously 2-3 days before and 2-3 days after first and final exercise session, after 12-week exercise intervention.

Secondary outcomes

  1. Change in adipose tissue nonesterified fatty acid (NEFA) metabolism.

    Determined using \[11C\]-palmitate with dynamic PET acquisition

    Time frame: Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  2. Change in lean organ (heart, liver, skeletal muscle) NEFA metabolism.

    Determined using \[11C\]-palmitate with dynamic PET acquisition

    Time frame: Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  3. Change in insulin sensitivity

    Determined by measuring circulating glucose, NEFA, insulin and C-peptide following the liquid meal.

    Time frame: Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  4. Change in dietary fatty acid oxidation

    Determined by measuring breath \[13C\]-carbon dioxide enrichment.

    Time frame: Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  5. Change in total substrate utilisation

    Determined using indirect calorimetry

    Time frame: Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  6. Change in postprandial plasma NEFA turnover.

    Determined using continuous infusion of \[7,7,8,8-2H\]-palmitate.

    Time frame: Blood sample collected every 60 min following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  7. Change in postprandial plasma glucose turnover

    Determined using continuous infusion of \[1-3H\]-glucose

    Time frame: Blood sample collected every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  8. Change in left ventricular function by Positron Emitting Positron (PET) ventriculography

    Determined using \[11C\]-palmitate combined with ECG-gated cardiac dynamic PET acquisition.

    Time frame: Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  9. Change in plasma distribution of DFA metabolites

    Determined using oral administration of \[18F\]-FTHA to quantify the incorporation of 18F-labeled fatty acids given with the liquid meal, into triglyceride-rich lipoproteins and NEFA.

    Time frame: Blood sample collected every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  10. Change in composition and activation status of immune cell subsets

    Determined by extensive Fluorescence Activated cell Sorting (FACS) analysis

    Time frame: Blood sample collected before and after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

  11. Change in plasma cytokine levels

    Determined by ELISA

    Time frame: Blood sample collected before and after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

07

Study locations

1 of 1 sites recruiting
  • Centre de recherche du CHUS
    Sherbrooke, Quebec J1H 5N4, Canada
    • Frédérique Frisch · Contact · frederique.frisch@usherbrooke.ca · 819-346-1110
    • Denis Blondin · Principal investigator
    • André Carpentier · Sub investigator
    • Éric Turcotte · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05123963
Lead sponsor
Université de Sherbrooke
Collaborators
University of Calgary, University of Waterloo, Laval University, Wageningen University, Maastricht University Medical Center, Leiden University Medical Center, McMaster University, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Responsible party
Sponsor
First posted
Nov 17, 2021
Start date
Sep 15, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
May 11, 2026

Study contacts

Frédérique Frisch
Contact
frederique.frisch@usherbrooke.ca
819-346-1110 ext. 12394
Denis P. Blondin, PhD
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion